Drug Detail

Information about XL-228

Generic Name
IND	XL-228
Brand Name (US)
Manufacturer	Exelixis
Drug Type	Tyrosine Kinase Inhibitor
Delivery	Intravenous
Approval Status	Phase 1
Indications
Overall Strategy	GIST cell based
Strategy	Block related tumor signal paths
Drug Category	IGF1R inhibitor

This is a IGF1R inhibitor in early development. IGF1R is overexpressed in 2/3 of wild-type GISTs and almost all pediatric GISTs.
Patients with wild-type GIST and pediatric GIST may be good candidates for a trial with inhibitors of IGF1R.
Since this drug is a multi-kinase inhibitor, it may have more side effects than IGF1R inhibitors that are more selective.